Skip to main content
. Author manuscript; available in PMC: 2020 Aug 3.
Published in final edited form as: Cancer Immunol Res. 2019 Oct 15;7(12):2013–2024. doi: 10.1158/2326-6066.CIR-19-0121

Figure 1.

Figure 1.

Comparisons of binding to cell lines and antibody dependent T cell–mediated cytotoxicity assays. A, GD2-BsAb and its Fc mutants binding to GD2+ melanoma cell line M14. B, HER2-BsAb and its Fc mutants binding to HER2+ breast cancer cell line AU565. C, GD2-BsAb and its Fc mutants redirected T-cell killing in 51Cr release assay of GD2+ neuroblastoma cell line IMR-32. Effector to target cell ratio was 10:1. D, HER2-BsAb and its Fc mutants redirected T-cell killing in 51Cr release assay of HER2+ breast cancer cell line AU565. Effector to target cell ratio was 10:1. The results shown are representative results from at least three independent repeats. No significant differences were observed between binding or cytotoxicity.